296 related articles for article (PubMed ID: 37033261)
21. A new nomogram model for prognosis of hepatocellular carcinoma based on novel gene signature that regulates cross-talk between immune and tumor cells.
Wang Y; Yang Y; Zhao Z; Sun H; Luo D; Huttad L; Zhang B; Han B
BMC Cancer; 2022 Apr; 22(1):379. PubMed ID: 35397536
[TBL] [Abstract][Full Text] [Related]
22. A Model of Basement Membrane-Associated Gene Signature Predicts Liver Hepatocellular Carcinoma Response to Immune Checkpoint Inhibitors.
Shen J; Wei Z; Lv L; He J; Du S; Wang F; Wang Y; Ni L; Zhang X; Pan F
Mediators Inflamm; 2023; 2023():7992140. PubMed ID: 37152370
[TBL] [Abstract][Full Text] [Related]
23. Identification of a Pyroptosis-Related Prognostic Signature Combined With Experiments in Hepatocellular Carcinoma.
Li H; Li T; Zhang X
Front Mol Biosci; 2022; 9():822503. PubMed ID: 35309514
[TBL] [Abstract][Full Text] [Related]
24. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
Front Immunol; 2022; 13():990790. PubMed ID: 36248822
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive analysis of diverse programmed cell death patterns in the prognosis, tumor microenvironment and drug sensitivity in hepatocellular carcinoma.
Yu Y; Lou Y; Zhu J; Wang X
Medicine (Baltimore); 2023 Dec; 102(48):e36239. PubMed ID: 38050240
[TBL] [Abstract][Full Text] [Related]
26. A novel mitochondrial unfolded protein response-related risk signature to predict prognosis, immunotherapy and sorafenib sensitivity in hepatocellular carcinoma.
Zhang S; Guo H; Wang H; Liu X; Wang M; Liu X; Fan Y; Tan K
Apoptosis; 2024 Jun; 29(5-6):768-784. PubMed ID: 38493408
[TBL] [Abstract][Full Text] [Related]
27. Integrative analysis unveils ECM signatures and pathways driving hepatocellular carcinoma progression: A multi-omics approach and prognostic model development.
Liu Z; Zhao P
J Cell Mol Med; 2024 Apr; 28(8):e18230. PubMed ID: 38568083
[TBL] [Abstract][Full Text] [Related]
28. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
[TBL] [Abstract][Full Text] [Related]
29. Five metastasis-related mRNAs signature predicting the survival of patients with liver hepatocellular carcinoma.
Chen C; Liu YQ; Qiu SX; Li Y; Yu NJ; Liu K; Zhong LM
BMC Cancer; 2021 Jun; 21(1):693. PubMed ID: 34116652
[TBL] [Abstract][Full Text] [Related]
30. Analysis and Validation of Tyrosine Metabolism-related Prognostic Features for Liver Hepatocellular Carcinoma Therapy.
Cui Z; Liu C; Li H; Wang J; Li G
Curr Med Chem; 2024 Feb; ():. PubMed ID: 38415454
[TBL] [Abstract][Full Text] [Related]
31. A degradome-based prognostic signature that correlates with immune infiltration and tumor mutation burden in breast cancer.
Luo Y; Ye Y; Chen Y; Zhang C; Sun Y; Wang C; Ou J
Front Immunol; 2023; 14():1140993. PubMed ID: 36993976
[TBL] [Abstract][Full Text] [Related]
32. Identification of hepatocellular carcinoma-related subtypes and development of a prognostic model: a study based on ferritinophagy-related genes.
Wang G; Li J; Zhu L; Zhou Z; Ma Z; Zhang H; Yang Y; Niu Q; Wang X
Discov Oncol; 2023 Aug; 14(1):147. PubMed ID: 37555866
[TBL] [Abstract][Full Text] [Related]
33. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
[TBL] [Abstract][Full Text] [Related]
34. Cuproptosis-Related Genes CDK1 and COA6 Involved in the Prognosis Prediction of Liver Hepatocellular Carcinoma.
Han S; Ye T; Mao Y; Hu B; Wang C
Dis Markers; 2023; 2023():5552798. PubMed ID: 37215201
[TBL] [Abstract][Full Text] [Related]
35. Development and validation of a robust immune-related risk signature for hepatocellular carcinoma.
Liu Z; Jiao D; Liu L; Zhou X; Yao Y; Li Z; Li J; Chen J; Lei Q; Han X
Medicine (Baltimore); 2021 Mar; 100(10):e24683. PubMed ID: 33725827
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive analysis of the amino acid metabolism-related gene signature for prognosis, tumor immune microenvironment, and candidate drugs in hepatocellular carcinoma.
Li Y; Mo H; Jia S; Wang J; Ma Y; Liu X; Tu K
Front Immunol; 2022; 13():1066773. PubMed ID: 36582227
[TBL] [Abstract][Full Text] [Related]
37. Identifying a Novel Endoplasmic Reticulum-Related Prognostic Model for Hepatocellular Carcinomas.
Ding F; Li J; Zhang Y; Wang C; Yu Y
Oxid Med Cell Longev; 2022; 2022():8248355. PubMed ID: 35915607
[TBL] [Abstract][Full Text] [Related]
38. Integration of single-cell RNA-seq and bulk RNA-seq to construct liver hepatocellular carcinoma stem cell signatures to explore their impact on patient prognosis and treatment.
Liu L; Zhang M; Cui N; Liu W; Di G; Wang Y; Xi X; Li H; Shen Z; Gu M; Wang Z; Jiang S; Liu B
PLoS One; 2024; 19(4):e0298004. PubMed ID: 38635528
[TBL] [Abstract][Full Text] [Related]
39. A novel prognostic model based on immunogenic cell death-related genes for improved risk stratification in hepatocellular carcinoma patients.
Liu T; Chen X; Peng B; Liang C; Zhang H; Wang S
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10255-10267. PubMed ID: 37269346
[TBL] [Abstract][Full Text] [Related]
40. A novel prognostic signature based on four glycolysis-related genes predicts survival and clinical risk of hepatocellular carcinoma.
Chen Z; Zou Y; Zhang Y; Chen Z; Wu F; Shi N; Jin H
J Clin Lab Anal; 2021 Nov; 35(11):e24005. PubMed ID: 34523732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]